Svetlana Nikic, Founder of Precision Oncology Consulting, shared a post on LinkedIn:
“Too many companies still treat Key Opinion Leader (KOL) engagement as an afterthought in market access. Regulatory approval is achieved, but reimbursement stalls because the right experts have not been mapped, activated, or aligned around the evidence story.
In precision oncology and diagnostics, KOLs are not only conference speakers. They are co-authors of the value proposition, validators of clinical utility, and essential voices for HTA and payer discussions. A fragmented, ad hoc approach wastes time and credibility.
When I work with clients, we build an end-to-end KOL Engagement Strategy for Market Access and Reimbursement that typically includes:
- Systematic mapping and segmentation of clinical and payer KOLs across key EU markets
- Clear engagement objectives linked to evidence gaps and upcoming access milestones
- Well-designed advisory boards and interviews that inform study design, value dossiers, and policy messages
- Continuous evidence alignment so that publications, conference outputs, and payer materials tell one coherent story
The outcome is not ‘more KOL meetings’, but a focused network of champions whose input directly accelerates reimbursement and adoption.
If you are planning European expansion for an oncology diagnostic or digital solution and want to stress-test your KOL strategy from a market access perspective, I would be happy to discuss it with you and your team.
Use this link to book a free 20-minute call with me.”
More posts featuring Svetlana Nikic.